DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story

starstarstarstarstar (1)
Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Women's Health Homepage

This microscope could spare women repeat breast cancer surgeries Light-sheet microscope can scan excised breast tissue for cancer cells in 30 minutes

Supplemental breast MR superior to ultrasound for screening breast cancer survivors But what about cost-effectiveness?

Researchers to undertake largest breast cancer clinical trial in Oklahoma Findings may have practice-changing implications

Mammogram screening and overdiagnosis: tumor size an issue? New NEJM report sparks opposing views in screening debate

Dog tumors help researchers understand human breast cancer Pathology test reveals cellular similarities

FDA approves Hologic's claim that Genius tomo is superior for dense breasts Only tomo solution on market with that distinction

Novartis and IBM Watson collaborate on outcomes-based breast cancer care Machine learning meets breast cancer expertise

Combining PET with optical imaging to ensure tumor margins in breast cancer surgery Cerenkov luminescence imaging could expand nuclear medicine

Study finds many early-stage breast cancer patients receive unnecessary testing Research to be presented at ASCO annual meeting

Breast screening bundle tool may offer radiologists a way forward under MACRA Seeking value in radiology-driven Advanced Payment Models

Molecular breast imaging finds cancers that mammograms don't: study

by Lisa Chamoff , Contributing Reporter
Molecular breast imaging (MBI) detected cancer in several women with dense breasts whose mammograms had been negative, with an incremental cancer detection rate of 7.7 per 1,000 screens, a study has found.

The retrospective study, published in the August issue of the American Journal of Roentgenology, examined data from the supplemental screening program at ProMedica Breast Care in Toledo, Ohio, from 2011 to 2014. After having a mammogram, 1,696 women with dense breast underwent supplementary screening with Gamma Medica’s LumaGEM MBI system, which uses the technetium-99m sestamibi radiopharmaceutical and employs a dual-head digital detector and a special collimator. This resulted in the detection of 13 malignancies, after the mammograms read negative for cancer.

Story Continues Below Advertisement

OR Tables, Treatment/GYN/Uro Chairs, Transport Stretchers, Hospital/ICU Bed

iMS combines the superior service of Oakworks Medical and advanced manufacturing technology of FAMED Medical Solutions. The goal of iMS, "Connecting Art and Medical Science" goes way beyond product with exceptional CareLink service. Contact us today!



“That’s a significant amount of extra cancers,” Dr. Robin Shermis, medical director at the ProMedica Breast Care Center and one of the study’s authors, told HCB News.

The lesion size ranged from .6 to 2.4 centimeters, with a mean of 1.1 centimeters. About 85 percent of the cancers were node negative, which means the prognosis was better.

“We found them early and they would have otherwise gone undetected by mammography,” Shermis said.

The study also found that the positive predictive value (PPV) for recall was 9.1 percent and the PPV for biopsy was 19.4 percent.

Shermis explained that patients at ProMedica Breast Care with a lifetime risk of at least 20 percent for developing breast cancer receive supplementary screening with MR, while patients with dense breast tissue are recommended to receive supplementary screening with MBI.

“MR is a great test, but it’s very expensive and insurance companies won’t pay for it unless you’re high risk,” Shermis said.

MBI delivers almost instantaneous results, he added.

“This new study in the AJR provides further evidence that women with dense breast tissue have more comfortable and less stressful alternatives to standardized secondary screening studies,” said Philip Croxford, chief executive officer of Gamma Medica, in a statement. “These recent clinical results suggest there is a real alternative to the risk of misdiagnosis and unnecessary biopsies.”

The study by ProMedica follows a study by the Mayo Clinic, published in the AJR last year, which found the addition of MBI to mammography increased the invasive breast cancer detection rate 363 percent, from 1.9 to 8.8 per 1,000 screens.

MBI uses 6 to 8 millicuries, about four times the dose from a digital mammogram, though Shermis said it’s possible to cut the dose in half by scanning for twice as long. While some breast cancer experts don’t recommend MBI for annual screening because of the higher dose, Shermis noted that it was important to weigh the risks with the benefit of detecting cancers earlier.

“Six thousand women, who know the benefits and risks, have yet to say ‘I don’t want it,’” Shermis said.

Women's Health Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED